Long Term Incentive Plan
Summary by AI BETAClose X
EKF Diagnostics Holdings plc
("EKF" or "the Company")
Long Term Incentive Plan
The Board recognises the importance of incentivising and rewarding the performance of its key executives, and having considered the views of certain of its shareholders, recently tasked the remuneration committee to recommend to the Board an appropriate long term incentive plan ("LTIP") for its senior executives.
The Board, following the recommendation of the remuneration committee and after consulting its advisers, has today made the following award (the "Award") to Gavin Jones (Chief Executive Officer) under the Company's newly established LTIP that was adopted on 9 September 2025:
|
Individual |
Position |
Type of Award |
Number of ordinary shares subject to LTIP award |
|
Gavin Jones |
Chief Executive Officer |
LTIP award - nominal cost option |
500,000 |
The Award has a performance period from the grant date to the third anniversary of the grant date and are subject to the following performance criteria.
The Award shall vest on a sliding scale depending on the total percentage growth of Adjusted EBITDA per share over the Performance Period, as follows:
(i) Growth of 25% or higher: 100% of the Award vests.
(ii) Between 10% and 25% growth: Vesting shall occur on a straight-line basis between 25% and 100%.
(iii) 10% growth: 25% of the Award vests; or
(iv) Below 10% growth: 0% of the Award vests.
Comment from the Chair of the Remuneration committee, Jenny Winter:
"It is important that Gavin is rewarded in a way which links his performance with shareholder value creation. I am satisfied that these incentivisation arrangements achieve that objective."
|
EKF Diagnostics Holdings plc |
||
|
Julian Baines, Executive Chair |
via Walbrook PR |
|
|
Gavin Jones, Chief Executive Officer |
|
|
|
Stephen Young, Chief Financial Officer
|
|
|
|
Singer Capital Markets (Nominated Adviser & Broker) |
Tel: +44 (0)20 7496 3000 |
|
|
Phil Davies / Oliver Platts |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
· Point-of-Care analysers in the key areas of Hematology and Diabetes.
· Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
|
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name |
Gavin Jones |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status |
Chief Executive Officer
|
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name
|
EKF Diagnostics Holdings plc |
|||
|
b)
|
LEI
|
213800DXTF3EAUK1AR05
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of 1 pence each |
|||
|
|
|
||||
|
Identification code |
GB0031509804
|
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of options over ordinary shares pursuant to the Company's LTIP |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1p |
500,000 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
n/a |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
16 September 2025 |
|||
|
f)
|
Place of the transaction
|
Outside a trading venue |
|||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 12 hours ago Johnson Matthey
- 13 hours ago Galliford Try
- 13 hours ago Galliford Try
- 13 hours ago Centrica
- 14 hours ago Smith & Nephew